![]() RxLive provides population health telepharmacy software and services powered by AI. ![]() This partnership empowers care teams to standardize across outpatient clinics, offering a consistent, high level of pharmacist intervention for medication therapy, disease management, and profile review.” “The right patient data helps care teams prioritize when and where patients need intervention to improve patient outcomes. “Outcomes and RxLive are delivering better care together,” says Stephen Bilotta, Vice President of Sales and Marketing at RxLive. “Through this collaboration with RxLive, we will continue to build on our work to connect health systems and providers with pharmacists so they can share valuable insights that will help patients navigate their care plan.” “Our mission is to help connect healthcare companies, patients, pharmacies and payers to create a more integrated experience that leads to better health outcomes for all,” said Brent Stutz, SVP of Outcomes. The more we know, the better we can serve the people we're caring for." ![]() “Providing a complete healthcare picture to the pharmacist at the point of care offers a big opportunity to both improve care and build trust. "Pharmacists have long been regarded as one of the most trustworthy healthcare team members by patients,” says Kristen Engelen, Chief Pharmacy Officer at RxLive. This functionality will be available to Outcomes’ network of more than 40,000 pharmacies nationwide. The collaboration between RxLive and Outcomes will address this problem by connecting data from enhanced clinic-based and post-discharge workflows, powered by My.RxLive, to the OutcomesOne™ platform to share relevant data on the patient’s care plan among all the providers involved in their treatment, reducing miscommunication that can lead to mismanagement of medication and harmful interactions. healthcare system billions of dollars each year, and recent studies show that approximately a quarter of potentially avoidable readmissions are medication related. 16, 2023 (GLOBE NEWSWIRE) - RxLive, today announced a collaboration with Outcomes, a Cardinal Health (NYSE: CAH) company, to improve data sharing and reduce communication gaps between hospitals, physicians and pharmacies. KKR teamed with Duke Rohlen in late 2020 to launch Zeus Health, a $100 million platform that invests in medical device companies.ST. Stephen Mason in 2019 replaced Jon Giacomin as CEO of Cardinal Health's medical segment and was tasked with addressing the operational and supply chain issues created by the acquisition of Cordis from J&J.Ĭordis manufacturing sites in Miami Lakes, Florida, Santa Clara, California, and Juarez, Mexico, will transition to H&F, whose partners in the deal include investment firm Ajax Health and startup Zeus Health. Additional costs of up to $125 million are anticipated to be incurred primarily in fiscal years 20. ![]() The company reported last month that s econd-quarter revenue for its medical segment increased 7% to $4.3 billion, driven by a net positive impact from COVID-19.Ĭardinal expects the Cordis divestiture to result in a pre-tax loss of up to $120 million in the third quarter of its fiscal year 2021. The exec also said Cardinal remains committed to its medical distribution and global medical products businesses, with a product portfolio generally more oriented around the operating and recovery rooms, including compression, enteral feeding, and wound care gauze dressings.Ĭardinal's customers for its medical product and supply chain services include hospitals, laboratories, physician offices, surgery centers, as well as patients in the home. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions.Ĭardinal CEO Mike Kaufmann said in a statement the decision to divest Cordis was based on efforts to focus resources on strategic growth areas "where we are an advantaged owner." In July, Cardinal was named as a defendant in 334 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,280 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava filter products. Cordis, which makes medical devices for diagnostics and interventional procedures to treat patients with coronary and peripheral vascular diseases, is an approximately $750 million revenue business.īut it's produced its share of headaches for Cardinal.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |